Fibroblast growth factor-23 is regulated by lα,25-dihydroxyvitamin D

被引:81
作者
Collins, MT [1 ]
Lindsay, JR
Jain, A
Kelly, MH
Cutler, CM
Weinstein, LS
Liu, J
Fedarko, NS
Winer, KK
机构
[1] Natl Inst Dental & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[2] NIH, Pediat & Reprod Endocrinol Branch, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[3] Johns Hopkins Univ, Dept Med, Div Geriatr Med, Baltimore, MD USA
[4] NIH, Nursing Serv, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[5] NIH, Patient Care Serv, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[6] NIDDKD, Metab Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
[7] Johns Hopkins Bayview Med Ctr, Gen Clin Res Ctr, Baltimore, MD USA
[8] Natl Inst Child Hlth, Bethesda, MD USA
[9] NIH, Human Dev Branch, Dept Hlth & Human Serv, Bethesda, MD USA
关键词
fibroblast growth factor-23; fibrous dysplasia; McCune-Albright syndrome; hypoparathyroidism; pseudohypoparathyroidism; phosphate; phosphorus; 1; alpha-hydroxylase; vitamin D; phosphaturia;
D O I
10.1359/JBMR.050718
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Fibroblast growth factor (FGF)-23 is a recently described hormone that has been shown to be involved in the regulation of phosphate and vitamin D metabolism. The physiologic role of FGF-23 in mineral metabolism and how serum FGF-23 levels are regulated have yet to be elucidated. Three patients with mineral metabolism defects that allowed for the investigation of the regulation of FGF-23 were studied. Materials and Methods: Patient 1 had postsurgical hypoparathyroidism and Munchausen's syndrome and consumed a pharmacologic dose of calcitriol. Patient 2 had postsurgical hypoparathyroidism and fibrous dysplasia of bone. She was treated with increasing doses of calcitriol followed by synthetic PTH(1-34). Patient 3 had pseudohypoparathyroidism type 113 and tertiary hyperparathyroidism. She underwent parathyroidectomy, which was followed by the development of hungry bone syndrome and hypocalcemia, requiring treatment with calcitriol. Serum FGF-23 and serum and urine levels of mineral metabolites were measured in all three patients. Results: Patient 1 had an acute and marked increase in serum FGF-23 (70 to 670 RU/ml; normal range, 18-108 RU/ml) within 24 h in response to high-dose calcitriol administration. Patient 2 showed stepwise increases in serum FGF-23 from 117 to 824 RU/ml in response to increasing serum levels of 1 alpha,25-dihydroxyvitamin D (1,25-D). Finally, before parathyroidectomy, while hypercalcemic, euphosphatemic, with low levels of 1,25-D (10 pg/ml; normal range, 22-67 pg/ml), and with very high serum PTH (863.7 pg/ml; normal range, 6.0-40.0 pg/ml), patient 3 had high serum FGF-23 levels (217 RU/ml). After surgery, while hypocalcemic, euphosphatemic, and with high serum levels of serum 1,25-D (140 pg/ml), FGF-23 levels were higher than preoperative levels (305 RU/ml). It seemed that the phosphaturic effect of FGF-23 was diminished in the absence of PTH or a PTH effect. Conclusions: Serum FGF-23 may be regulated by serum 1,25-D, and its phosphaturic effect may be less in the absence of PTH.
引用
收藏
页码:1944 / 1950
页数:7
相关论文
共 38 条
[1]   Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders [J].
Bai, XY ;
Miao, DS ;
Li, JR ;
Goltzman, D ;
Karaplis, AC .
ENDOCRINOLOGY, 2004, 145 (11) :5269-5279
[2]   An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia [J].
Benet-Pagès, A ;
Orlik, P ;
Strom, TM ;
Lorenz-Depiereux, B .
HUMAN MOLECULAR GENETICS, 2005, 14 (03) :385-390
[3]   Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsα-mutated skeletal progenitor cells [J].
Bianco, P ;
Kuznetsov, SA ;
Riminucci, M ;
Fisher, LW ;
Spiegel, AM ;
Robey, PG .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1737-1744
[4]   ASSESSMENT OF PHOSPHATE REABSORPTION [J].
BIJVOET, OLM ;
MORGAN, DB ;
FOURMAN, P .
CLINICA CHIMICA ACTA, 1969, 26 (01) :15-+
[5]   What have we learnt about the regulation of phosphate metabolism? [J].
Blumsohn, A .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2004, 13 (04) :397-401
[6]   FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate [J].
Bowe, AE ;
Finnegan, R ;
de Beur, SMJ ;
Cho, J ;
Levine, MA ;
Kumar, R ;
Schiavi, SC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 284 (04) :977-981
[7]   Involution of the adrenal glands in newly born infants - A biochemical inquiry into its physiologic significance [J].
Bruch, H ;
McCune, DJ .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1936, 52 (04) :863-869
[8]   INHIBITION OF RENAL PHOSPHATE-TRANSPORT BY A TUMOR PRODUCT IN A PATIENT WITH ONCOGENIC OSTEOMALACIA [J].
CAI, Q ;
HODGSON, SF ;
KAO, PC ;
LENNON, VA ;
KLEE, GG ;
ZINSMIESTER, AR ;
KUMAR, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (23) :1645-1649
[9]   Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors [J].
Carpenter, TO ;
Ellis, BK ;
Insogna, KL ;
Philbrick, WM ;
Sterpka, J ;
Shimkets, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02) :1012-1020
[10]   Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: Core biopsy studies and clinical correlations [J].
Corsi, A ;
Collins, MT ;
Riminucci, M ;
Howell, PGT ;
Boyde, A ;
Robey, PG ;
Bianco, P .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (07) :1235-1246